Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab combined with anlotinib for PD-1/PD-L1-resistant advanced non-small cell lung cancer
ChiCTR2200066655Phase 2Recruiting
- Sponsor
- Fuzhou First Hospital
- Start
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Fuzhou First Hospital. Primary endpoint: Objective response rate. Started Dec 2022; status: recruiting.
02
Drugs
zimberelimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200066655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066655.